In contrast, there was a statistically significant difference in proliferation of CD34+ control cells in comparison to CD34+ CML cells treated with IM or DN-Gas2 alone (p<0.001, n=3 comparing either condition to control cells at each cytokine dose). This evidence concerns the gene GAS2 and chronic myelogenous leukemia, BCR-ABL1 positive.